New agents and regimens for diffuse large B cell lymphoma
Abstract As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2020-12-01
|
| coleção: | Journal of Hematology & Oncology |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s13045-020-01011-z |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|